Iambic Therapeutics
Iambic's AI-Designed HER2 Drug IAM1363 Shows Durable Responses at ESMO 2026
Iambic Therapeutics has presented updated Phase 1/1b data for IAM1363, a selective, brain-penetrant HER2 tyrosine kinase inhibitor, showing durable anti-tumor activity…
Iambic prices IPO at $16 a share, raising $150.0 million on Nasdaq
Iambic Therapeutics, a clinical-stage company that uses an AI-driven platform to develop medicines, has priced its initial public offering of 9,375,000 shares at $16.00…